Novogene Co., Ltd. Hits Day Low at CNY 14.08 Amid Price Pressure

Novogene Co., Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable decline today, with its stock price dropping by 5.1%. The stock reached an intraday low of CNY 14.08, reflecting ongoing challenges in its performance metrics. Over the past week, Novogene's stock has decreased by 4.07%, and its monthly performance shows a decline of 2.62%. In contrast, the China Shanghai Composite has shown a more modest decline of 1.08% over the same week and 0.95% over the month. Despite a year-to-date performance of 6.48%, which surpasses the Shanghai Composite's 2.51%, Novogene has struggled significantly over longer periods. The stock has plummeted by 54.11% over the past three years and 71.11% over the last five years, indicating a consistent underperformance against the benchmark. Key financial metrics reveal a P/E ratio of 36.00 and a return on equity of 5.86%, while the company has reported negative results in March 2025 after two consecutive positive quarters. These factors contribute to the stock's current position in the market.